Adamas Pharmaceuticals Inc (ADMS) saw its loss widen to $14.96 million, or $0.68 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $10.69 million, or $0.58 a share.

Revenue during the quarter plunged 92.94 percent to $0.04 million from $0.52 million in the previous year period.

Operating loss for the quarter was $15.29 million, compared with an operating loss of $16.06 million in the previous year period.

"We expect 2017 to be a pivotal year as we transform from an R&D-focused company to a commercial organization as we anticipate FDA approval of ADS-5102 for the treatment of levodopa-induced dyskinesia. If approved, we expect to launch ADS-5102 in the second half of 2017, providing Parkinson’s patients with the first and only medicine indicated for the treatment of levodopa-induced dyskinesia," said Gregory T. Went, Ph.D., chairman and chief executive officer of Adamas Pharmaceuticals, Inc. "In addition, we are continuing to develop ADS-5102 in additional indications, as well as to advance the clinical development of ADS-4101 for the treatment of partial onset seizures in patients with epilepsy, the fourth chrono-synchronous targeted therapy to emerge from our drug development platform."

The company has spent $26.71 million cash to meet investing activities during the year as against cash inflow of $8.06 million in the last year.

Cash flow from financing activities was $65.41 million for the year, up 505.07 percent or $54.60 million, when compared with the last year.

Cash and cash equivalents stood at $23.74 million as on Dec. 31, 2016, down 28.30 percent or $9.37 million from $33.10 million on Dec. 31, 2015.

Working capital increases
Adamas Pharmaceuticals Inc has recorded an increase in the working capital over the last year. It stood at $107.24 million as at Dec. 31, 2016, up 5.78 percent or $5.86 million from $101.38 million on Dec. 31, 2015. Current ratio was at 12.01 as on Dec. 31, 2016, up from 9.59 on Dec. 31, 2015.